PHARMACIE DELALANDE - LE DANTEC : revenue, balance sheet and financial ratios

PHARMACIE DELALANDE - LE DANTEC is a French company founded 11 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75011), this company of category PME shows in 2019 a revenue of 1.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DELALANDE - LE DANTEC (SIREN 807489620)
Indicator 2023 2022 2021 2019 2018 2017 2016
Revenue N/C N/C N/C 1 824 010 € 1 766 355 € 1 723 350 € 1 671 592 €
Net income 9 881 € 104 639 € 106 645 € 57 778 € 86 454 € 78 593 € 120 231 €
EBITDA N/C N/C N/C 133 690 € 165 513 € 165 280 € 168 632 €
Net margin N/C N/C N/C 3.2% 4.9% 4.6% 7.2%

Revenue and income statement

In 2023, PHARMACIE DELALANDE - LE DANTEC generates positive net income of 10 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2023: 120 k€ -> 10 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

9 881 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 173%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 30%. The balance between equity and debt is satisfactory.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

173.44%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

30.256%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

1.7%

Solvency indicators evolution
PHARMACIE DELALANDE - LE DANTEC

Sector positioning

Debt ratio
173.44 2023
2021
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.24
Average

In 2023, the debt ratio of PHARMACIE DELALANDE - LE ... (173.44) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
30.26% 2023
2021
2022
2023
Q1: 28.72%
Med: 48.51%
Q3: 68.17%
Average

In 2023, the financial autonomy of PHARMACIE DELALANDE - LE ... (30.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 74.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

74.339

Liquidity indicators evolution
PHARMACIE DELALANDE - LE DANTEC

Sector positioning

Liquidity ratio
74.34 2023
2021
2022
2023
Q1: 135.25
Med: 189.78
Q3: 270.35
Watch -6 pts over 3 years

In 2023, the liquidity ratio of PHARMACIE DELALANDE - LE ... (74.34) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 117 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1246 days. Excellent situation: suppliers finance 1129 days of the operating cycle (retail model).

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

117 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

1246 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DELALANDE - LE DANTEC

Positioning of PHARMACIE DELALANDE - LE DANTEC in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2023, the value of PHARMACIE DELALANDE - LE DANTEC is estimated at 116 590 € (range 70 904€ - 163 900€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
220 transactions
70k€ 116k€ 163k€
116 590 € Range: 70 904€ - 163 900€
NAF 5 année 2023

Valuation method used

Net Income Multiple
9 881 € × 11.8x = 116 591 €
Range: 70 904€ - 163 900€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DELALANDE - LE DANTEC with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DELALANDE - LE DANTEC

What is the revenue of PHARMACIE DELALANDE - LE DANTEC ?

The revenue of PHARMACIE DELALANDE - LE DANTEC in 2019 is 1.8 M€.

Is PHARMACIE DELALANDE - LE DANTEC profitable?

Yes, PHARMACIE DELALANDE - LE DANTEC generated a net profit of 10 k€ in 2023.

Where is the headquarters of PHARMACIE DELALANDE - LE DANTEC ?

The headquarters of PHARMACIE DELALANDE - LE DANTEC is located in PARIS (75011), in the department Paris.

Where to find the tax return of PHARMACIE DELALANDE - LE DANTEC ?

The tax return of PHARMACIE DELALANDE - LE DANTEC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DELALANDE - LE DANTEC operate?

PHARMACIE DELALANDE - LE DANTEC operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.